戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1       Severe periodontitis prevalence was higher in the OSA group than control group.
2 at 2 weeks and 1-month were significantly lower for the R-E group than for the NR-E group (treatment main effect: F1,68 =
3 mptom scores for pain were significantly higher in the TTIL group than in TAMK for 2 years postoperatively (P = 0.036).
4 al stay (11 vs 12 days; P = .50), was longer in the 48-hour group than in the 24-hour group.
5 al Performance Test score increased more in the combination group than in the aerobic and resistance groups (27.9 to 33.4
6 ractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 20
7 on cancer risk was higher in the proinflammatory-change DII group than in the antiinflammatory-stable DII group (hazard r
8 nt initiation were significantly higher in the blinatumomab group than in the chemotherapy group, both with respect to co
9 .51; P < 0.001) after the intervention was lower in the YCF group than in the CM group.
10 -ART initiation was significantly lower in the intervention group than in the control group (31 [33%] of 94 participants
11 ession-free survival were significantly longer in the study group than in the control group (both were 28 months vs 10 mo
12 elihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or th
13 likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37
14 rsion in liquid media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 62 days, a
15 l, we identified more infections (n = 146) in the denosumab group than in the control group (n = 99).
16 ignificantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone respons
17 rations were persistently lower in the sacubitril/valsartan group than in the enalapril group over the 3-year follow-up (
18 3]; p<0.0001) were significantly higher in the EUC plus CAP group than in the EUC alone group, but we noted no effect on
19 FeFum+NaFeEDTA compared with FeSO4 was higher in the Fe+GOS group than in the Fe group (88% compared with 63%; P = 0.006)
20     There were more reports of diarrhea in the iron complex group than in the ferrous sulfate group (58% vs 35%, respecti
21 mean levels of several PCB congeners were higher in the ASD group than in the ID and GP groups.
22   Development of ischemic MR was more pronounced in the LAI group than in the LCx group.
23     On Day 2, PaO2/FiO2 ratio was higher in the sevoflurane group than in the midazolam group (mean +/- SD, 205 +/- 56 vs
24 sion-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 mo
25        The rate of VOCE was higher in the positive mismatch group than in the negative mismatch group (hazard ratio, 0.38
26 es, and relative to the pretreatment period) in SLIT tablet group than in the non-AIT group (P<.001).
27 tal deaths were significantly higher in the hypoalbuminemic group than in the non-hypoalbuminemic group (6.6% vs 3.1%, P
28 ntly more restrictive (lower median CCS) in the hemorrhagic group than in the nonhemorrhagic group (1 vs 6.5; P < .001).
29  more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01).
30 njection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001).
31 ia, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard
32 iltration rate increased (P=0.003) more in the elamipretide group than in the placebo group (P=0.11).
33 rse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting,
34 l attendance with exacerbations was 27% lower in the active group than in the placebo group, but this did not reach signi
35 d and the MMP2 and MMP9 were significantly higher in the VD group than in the placebo group.
36 ramps and hypophosphatemia were more common in the imatinib group than in the placebo group.
37 iter) or below was significantly lower in the sotagliflozin group than in the placebo group.
38 om from relapse were also higher in the combination-therapy group than in the placebo group.
39                 Dizziness was more common in the pregabalin group than in the placebo group.
40 ommittee found a higher number of deaths in the rilotumumab group than in the placebo group; all patients in the rilotumu
41                      Fewer participants in the dolutegravir group than the atazanavir group reported drug-related adverse
42 ain intensity across follow-up to 12 mo in the intervention group than the control group (adjusted mean difference 0.31;
43 cal activity behaviors were 99% higher for the intervention group than the control group (P = 0.008).This mHealth obesity
44 LCO intervention groups but were longer in the PLCO control group than the ERSPC control group.
45 ing were significantly higher in the high sputum eosinophil group than the low sputum eosinophil group.
46 .3.2, and 2.3.4) were detected in the LAIV H5N2 experienced group than the naive group (p<0.0001).
47 atment failure was significantly higher for the intravenous group than the oral group [odds ratio (OR) 1.74, 95% confiden
48        The mean cost was lower in the pasireotide (n = 152) group than the placebo (n = 148) group; however, this did not
49                Adverse events were more frequent in the KGF group than the placebo group (14 vs 5 events; odds ratio 4.9,
50       A significantly greater mean DDR% was found in the MF group than the placebo group at 6 and 9 months in both subgro

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。